Why is Aarti Drugs falling/rising?

As of 04-Aug, Aarti Drugs Ltd is currently priced at 492.30, reflecting an increase of 2.85 or 0.58%. The stock has shown a trend reversal, gaining after three consecutive days of decline. It is performing in line with its sector today, and the delivery volume has risen significantly, indicating increased investor participation. Despite a one-year return of -4.18%, the company has experienced a profit increase of 20.4%, and it is trading at a discount compared to its peers. The company also boasts a high return on capital employed (ROCE) of 17.84% and a low debt-to-equity ratio of 0.45, which contribute positively to its valuation and attractiveness as an investment. In the broader market context, Aarti Drugs' short-term performance has been underwhelming, with a one-week return of -6.63%, while the benchmark Sensex has gained 0.16%. However, over the longer term, the stock has outperformed the benchmark year-to-date with a return of 6.87% compared to the Sensex's 3.69%. This suggests that while the stock has faced recent challenges, its overall performance remains relatively strong in the context of the market, particularly given its solid fundamentals and management efficiency.